June 1, 2024 | Volume 12 | Number 6

CANCER IMMUNOLOGY RESEARCH
TABLE OF CONTENTS

WHAT WE'RE READING

REVIEW

PRIORITY BRIEF

RESEARCH ARTICLES

TABLE OF CONTENTS

TABLE OF CONTENTS

ABOUT THE COVER

Recombinant cytokines show limited utility as a cancer treatment because the high doses needed for an antitumor effect cause severe systemic toxicities. After finding that IL18 is upregulated in the tumor microenvironment (TME) but is mostly inactive because it is bound to IL18 binding protein (IL18BP), Menachem and Alteber et al. generated an IL18BP-specific antibody that can displace IL18 from IL18:IL18BP complexes, activating $CD8^+$ T cells and NK cells. A mouse surrogate for the human antibody inhibited tumor growth in several mouse models concomitant with TME immune activation. No effects were observed in the periphery, highlighting the potential of blocking IL18BP to therapeutically harness naturally occurring IL18 in the TME. Read more in this issue on page 687. Original image from Fig. 7A. Artwork by Lewis Long.



doi: 10.1158/2326-6066.CIR-12-6-CVR

NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR's established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.